Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A - Coyle, T. E.; Reding, M. T.; Lin, J. C.; Michaels, L. A.; Shah, A.; Powell, J. (Journal of thrombosis and haemostasis, 2014)
Keywords: Adult; Animals; Clinical Haemostasis and Thrombosis; clinical trial, Phase 1; Factor VIII - chemistry; Factor VIII - pharmacokinetics; factor VIII; Hemophilia; Hemophilia A - blood; Hemophilia A - drug therapy; hemophilia A; Humans; Male; Middle Aged; Peptide Fragments - chemistry; Peptide Fragments - pharmacokinetics; pharmacokinetics; Polyethylene Glycols - chemistry; Polyethylene Glycols - pharmacokinetics; Prospective Studies; recombinant proteins; Recombinant Proteins - chemistry; Recombinant Proteins - pharmacokinetics; Treatment Outcome; Young Adult